-
公开(公告)号：US20230065527A1
公开(公告)日：2023-03-02
申请号：US17444947
申请日：2021-08-12
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez , Antitsa Dimitrova Stoycheva , Jerome Deval , Cheng Liu , Qingling Zhang
IPC: C07D487/10 , C07D519/00 , C07D401/14 , C07D491/107 , C07D491/048 , C07D471/04
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US20240277706A1
公开(公告)日：2024-08-22
申请号：US18415432
申请日：2024-01-17
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez
IPC: A61K31/501 , A61K31/506 , A61K45/06 , C07D401/14
CPC classification number: A61K31/501 , A61K31/506 , A61K45/06 , C07D401/14
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US20230192713A1
公开(公告)日：2023-06-22
申请号：US18066507
申请日：2022-12-15
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez
IPC: C07D487/10 , C07D403/14 , C07D401/14 , C07D405/14 , C07D401/12 , C07D471/08 , C07D413/14 , C07D498/04
CPC classification number: C07D487/10 , C07D403/14 , C07D401/14 , C07D405/14 , C07D401/12 , C07D471/08 , C07D413/14 , C07D498/04
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US20230002413A1
公开(公告)日：2023-01-05
申请号：US17303089
申请日：2021-05-19
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Antitsa Dimitrova Stoycheva , Francois Gonzalvez , Jerome Deval , Cheng Liu
IPC: C07D519/00 , C07C229/16 , C07C215/14 , C07C233/36 , C07D207/267 , C07D295/135 , C07D217/02 , C07D209/44 , C07C211/42 , C07D205/12 , C07D491/107 , C07D217/04 , C07D401/14 , C07D471/04
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US11760764B2
公开(公告)日：2023-09-19
申请号：US17303089
申请日：2021-05-19
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Antitsa Dimitrova Stoycheva , Francois Gonzalvez , Jerome Deval , Cheng Liu
IPC: C07D519/00 , C07C229/16 , C07C215/14 , C07D233/36 , C07D207/267 , C07D295/135 , C07D217/02 , C07D209/44 , C07C211/42 , C07D205/12 , C07D491/107 , C07D217/04 , C07D401/14 , C07D471/04 , C07C233/36
CPC classification number: C07D519/00 , C07C211/42 , C07C215/14 , C07C229/16 , C07C233/36 , C07D205/12 , C07D207/267 , C07D209/44 , C07D217/02 , C07D217/04 , C07D295/135 , C07D401/14 , C07D471/04 , C07D491/107 , C07C2602/08
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US20230031213A1
公开(公告)日：2023-02-02
申请号：US17807083
申请日：2022-06-15
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez , Antitsa Dimitrova Stoycheva , Cheng Liu , Jerome Deval , David McGowan
IPC: C07D401/14 , C07D491/048 , C07D487/10 , C07D405/14 , C07D403/12 , C07D401/12 , C07D498/10 , C07D471/04 , C07D519/00 , C07D413/14
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US20240376078A1
公开(公告)日：2024-11-14
申请号：US18658848
申请日：2024-05-08
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez , Antitsa Dimitrova Stoycheva , Cheng Liu , Jerome Deval , David McGowan
IPC: C07D401/14 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/10 , C07D491/048 , C07D498/10 , C07D519/00
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US12018015B2
公开(公告)日：2024-06-25
申请号：US17807083
申请日：2022-06-15
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez , Antitsa Dimitrova Stoycheva , Cheng Liu , Jerome Deval , David McGowan
IPC: C07D401/14 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/10 , C07D491/048 , C07D498/10 , C07D519/00
CPC classification number: C07D401/14 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/10 , C07D491/048 , C07D498/10 , C07D519/00
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US11760761B2
公开(公告)日：2023-09-19
申请号：US17444947
申请日：2021-08-12
Applicant: Aligos Therapeutics, Inc.
Inventor： Tongfei Wu , Pierre Jean-Marie Bernard Raboisson , Francois Gonzalvez , Antitsa Dimitrova Stoycheva , Jerome Deval , Cheng Liu , Qingling Zhang
IPC: C07D487/10 , C07D401/14 , C07D471/04 , C07D491/048 , C07D491/107 , C07D519/00
CPC classification number: C07D487/10 , C07D401/14 , C07D471/04 , C07D491/048 , C07D491/107 , C07D519/00
Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
-
公开(公告)号：US20220112194A1
公开(公告)日：2022-04-14
申请号：US17217193
申请日：2021-03-30
Applicant: ALIGOS THERAPEUTICS, INC.
Inventor： Koen Vandyck , Pierre Jean-Marie Bernard Raboisson , Jerome Deval , Leonid Beigelman , David McGowan , Yannick Debing , Francois Gonzalvez
IPC: C07D487/04 , C07D519/00 , C07D471/04 , A61P35/00
Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
